Oppenheimer Has Lowered Expectations for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lowered by Oppenheimer from $190.00 to $180.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the stock. Wells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday. StockNews.com downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. TD Cowen increased their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Stock Down 3.6 %

Ascendis Pharma A/S stock opened at $122.00 on Friday. The firm has a market cap of $7.40 billion, a PE ratio of -15.10 and a beta of 0.66. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The company’s 50 day moving average is $132.40 and its two-hundred day moving average is $132.47.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its position in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after purchasing an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC grew its position in Ascendis Pharma A/S by 82.3% during the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 11,223 shares during the last quarter. SG Americas Securities LLC grew its position in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after purchasing an additional 4,205 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.